Knowledge Management System of Hefei Institute of Physical Science,CAS
Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens | |
Cao, Fei; Zheng, Jiaping; Luo, Jun; Zhang, Zhewei; Shao, Guoliang | |
2021-07-24 | |
发表期刊 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
![]() |
ISSN | 0171-5216 |
通讯作者 | Shao, Guoliang(guofu330@163.com) |
摘要 | Objective This study aimed to evaluate the efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization (DEB-TACE) versus regorafenib monotherapy in colorectal cancer liver metastases (CRLM) patients who failed standard treatment regimens. Methods Totally, 76 eligible CRLM patients were analyzed, among which 42 patients received regorafenib monotherapy (as regorafenib group) and 34 patients received regorafenib plus DEB-TACE (as regorafenib plus DEB-TACE group). Results Objective response rate (35.3% versus 7.1%, P=0.002) and disease control rate (76.5% versus 47.6%, P=0.011) were both increased in regorafenib plus DEB-TACE group compared with regorafenib group; meanwhile, negative conversion rate of carcinoembryonic antigen (66.7% versus 28.6%, P=0.008) after treatment was elevated in regorafenib plus DEB-TACE group compared with regorafenib group. Notably, progression-free survival (PFS) (median value: 7.6 versus 4.1 months, P<0.001) and overall survival (OS) (median value: 15.7 versus 9.2 months, P<0.001) were both higher in regorafenib plus DEB-TACE group compared with regorafenib group. Furthermore, liver function indexes (alanine transaminase, aspartate aminotransferase, and cholinesterase levels) after treatment were all similar between the two groups (all P>0.05). In addition, the occurrences of upper abdominal distending pain (P<0.001), nausea and vomiting (P=0.002) and fever (P=0.002) were higher in regorafenib plus DEB-TACE group compared with regorafenib group, while the majority of these adverse events were mild and tolerable. Conclusions Regorafenib plus DEB-TACE is superior to regorafenib monotherapy regarding treatment response, PFS and OS, while induces tolerable post-embolization syndrome in CRLM patients who fail standard treatment regimens. |
关键词 | Regorafenib plus DEB-TACE CRLM Treatment response Prognosis Adverse events |
DOI | 10.1007/s00432-021-03708-1 |
关键词[WOS] | TACE ; MELANOMA |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Medicine and health discipline platform project of zhejiang province[2018RC019] ; Medicine and health discipline platform project of zhejiang province[2020KY483] |
项目资助者 | Medicine and health discipline platform project of zhejiang province |
WOS研究方向 | Oncology |
WOS类目 | Oncology |
WOS记录号 | WOS:000676080100001 |
出版者 | SPRINGER |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/123270 |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Shao, Guoliang |
作者单位 | Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp, Dept Intervent Radiol,Canc Hosp,Univ Chinese Acad, 1 Banshan Dong Lu, Hangzhou 310022, Zhejiang, Peoples R China |
推荐引用方式 GB/T 7714 | Cao, Fei,Zheng, Jiaping,Luo, Jun,et al. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2021. |
APA | Cao, Fei,Zheng, Jiaping,Luo, Jun,Zhang, Zhewei,&Shao, Guoliang.(2021).Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. |
MLA | Cao, Fei,et al."Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论